Cassava Announces Closure of U.S. Department of Justice Investigation
MWN-AI** Summary
Cassava Sciences, Inc. (NASDAQ: SAVA), a biotechnology company focused on treatments for central nervous system disorders, announced the closure of an investigation by the U.S. Department of Justice (DOJ) concerning allegations of research misconduct. This inquiry, linked to the case of United States v. Wang, was dismissed with prejudice on October 23, 2025, marking the end of a significant legal chapter for the company. Cassava had previously settled with the U.S. Securities and Exchange Commission (SEC) in September 2024 over negligence-based disclosure charges, paying a monetary penalty without admitting to or denying the allegations.
Richard J. Barry, the company’s President and CEO, welcomed the conclusion of these investigations, emphasizing Cassava's commitment to maintaining trust with stakeholders and focusing on its primary objective: developing innovative treatments for Tuberous Sclerosis Complex-related epilepsy. The closure of these legal matters allows Cassava to redirect its energies toward advancing its investigational products, including simufilam.
In light of this resolution, Cassava reiterated the importance of transparency and adherence to regulatory standards in its ongoing research and development efforts. The company recognizes the inherent risks in drug discovery and highlights that all its investigational products remain unapproved by any regulatory authority as they advance through the development process.
The closure of these investigations aligns with Cassava's commitment to ethical practices while navigating the complexities of the biotechnology landscape. Moving forward, investors are encouraged to review the company's filings with the SEC, which detail potential risks related to its business and ongoing research activities, ensuring informed decisions regarding their investments.
MWN-AI** Analysis
Cassava Sciences, Inc. (NASDAQ: SAVA) has recently announced the closure of investigations by both the U.S. Department of Justice (DOJ) and the Securities and Exchange Commission (SEC). This news significantly reduces uncertainty surrounding the company, which has been under scrutiny following allegations of research misconduct and negligence-based disclosure. The dismissal of the DOJ indictment and the SEC settlement, where Cassava neither admitted nor denied wrongdoing, allows the company to refocus on its core mission: developing innovative treatments for central nervous system disorders, specifically Tuberous Sclerosis Complex (TSC)-related epilepsy.
From a market perspective, this development could be seen as a bullish indicator for Cassava Sciences. Confidence from investors typically hinges on legal clarity, and the resolution of these inquiries is likely to improve investor sentiment. Furthermore, as Cassava continues its exploration in the promising field of CNS disorder treatments, its lead candidate, simufilam, has the potential to attract increased attention given the growing demand for effective therapies in this area.
However, it is crucial for investors to remain cautious. The biotechnology sector is often characterized by significant volatility and risk, particularly when it comes to drug development. As noted, the outcomes of research and development efforts are uncertain, and the approval process can entail prolonged periods before any potential commercialization occurs.
Investors should also review the comprehensive risk factors outlined in Cassava's SEC filings, which emphasize the complexities involved in drug discovery and development. While the current news is positive, potential shareholders must weigh potential rewards against inherent risks. Keeping an eye on clinical trial results and market reactions will be key indicators of Cassava's trajectory going forward. Overall, while the closure of these investigations is favorable, prudence is advised before making investment decisions.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
AUSTIN, Texas, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders such as Tuberous Sclerosis Complex (TSC)-related epilepsy, today announced that the U.S. Department of Justice Fraud Section (DOJ) has closed its inquiry into the Company regarding allegations of research misconduct as described in the indictment in United States v. Wang, 8:24-cr-000211-TDC (D. Md.). That indictment was dismissed with prejudice by DOJ on October 23, 2025.
As previously disclosed, the Company reached a settlement with the U.S. Securities and Exchange Commission (SEC) of negligence-based disclosure charges in September 2024 and paid a monetary penalty without admitting or denying the SEC’s allegations.
The Company cooperated fully with both the DOJ and SEC investigations. These outcomes end the investigations of the Company by the DOJ and SEC.
“We welcome the resolution of these investigations and remain dedicated to maintaining the trust of all our stakeholders. As we move forward, we will continue to focus our efforts on developing a novel treatment for TSC-related epilepsy,” said Richard J. Barry, President and Chief Executive Officer of Cassava.
About Cassava Sciences, Inc.
Cassava Sciences, Inc. (NASDAQ: SAVA), is a biotechnology company focused on developing novel, investigational treatments, including simufilam, for central nervous system disorders, such as tuberous sclerosis complex (TSC)-related epilepsy, and potentially other indications.
For more information, please visit: https://www.CassavaSciences.com
For More Information Contact:
Investors
Sandya von der Weid
svonderweid@lifesciadvisors.com
Company
Eric Schoen, Chief Financial Officer
(512) 501-2450
ESchoen@CassavaSciences.com
IR@cassavasciences.com
Cautionary Note Regarding Forward-Looking Statements: add a few notes on the paper
This news release contains forward-looking statements. Forward-looking statements may be identified by words such as “anticipate”, “before”, “believe”, “could”, “expect”, “forecast”, “intend”, “may”, ”pending”, “plan”, “possible”, “potential”, “prepares for”, “will”, and other words and terms of similar meaning.
Such statements are based on our current expectations and projections about future events. Such statements speak only as of the date of this news release and are subject to a number of risks, uncertainties and assumptions, including, but not limited to, those risks inherent in drug discovery and development or specific to Cassava Sciences, Inc., as described in the section entitled “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2024 and Quarterly Report on Form 10-Q for the period ended September 30, 2025, and subsequent reports periodically filed and to be filed with the SEC. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from expectations in any forward-looking statement. In light of these risks, uncertainties and assumptions, the forward-looking statements and events discussed in this news release are inherently uncertain and may not occur, and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Accordingly, you should not rely upon forward-looking statements as predictions of future events. Except as required by law, we disclaim any intention or responsibility for updating or revising any forward-looking statements. For further information regarding these and other risks related to our business, investors should consult our filings with the SEC, which are available on the SEC's website at www.sec.gov.
All of our pharmaceutical assets under development are investigational product candidates. These have not been approved for use in any medical indication by any regulatory authority in any jurisdiction and their safety, efficacy or other desirable attributes, if any, have not been established in any patient population. Consequently, none of our product candidates is approved or available for sale anywhere in the world.
Our clinical results from earlier-stage clinical trials or preclinical studies may not be indicative of future results from later-stage or larger scale clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements or any scientific data we present or publish.
We are in the business of new drug discovery and development. Our research and development activities are long, complex, costly and involve a high degree of risk. Holders of our common stock should carefully read our Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q and any other SEC filings in their entirety, including the risk factors therein. Because risk is fundamental to the process of drug discovery and development, you are cautioned to not invest in our publicly traded securities unless you are prepared to sustain a total loss of the money you have invested.
FAQ**
How has the closure of the U.S. DOJ inquiry impacted investor confidence in Cassava Sciences Inc. (SAVA) and its ongoing projects in CNS disorders?
What are the key next steps for Cassava Sciences Inc. (SAVA) following the resolution of investigations by the DOJ and SEC?
How does Cassava Sciences Inc. (SAVA) plan to strengthen its compliance and oversight mechanisms to regain stakeholder trust?
What updates can investors expect from Cassava Sciences Inc. (SAVA) regarding its investigational treatments for TSC-related epilepsy in the coming months?
**MWN-AI FAQ is based on asking OpenAI questions about Cassava Sciences Inc. (NASDAQ: SAVA).
NASDAQ: SAVA
SAVA Trading
4.52% G/L:
$2.08 Last:
307,876 Volume:
$2.01 Open:
